AtriCure, Inc.

AtriCure Inc. (NASDAQ: ATRC) is a leading innovator in surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain management. The company operates through its website at www.atricure.com and serves the global cardiac and thoracic surgery markets with a comprehensive portfolio of ablation, appendage management, and pain management solutions.

The company's core business centers on products that enable surgeons to perform ablation and left atrial appendage exclusion procedures with faster, less invasive, and clinically proven approaches. AtriCure's ablation products utilize either radiofrequency or cryogenic energy modalities and include the Isolator Synergy Clamps, EnCompass Clamp, multifunctional pens, linear ablation devices, cryoICE Cryoablation System, and EPi-Sense Systems. For appendage management, the company offers its flagship AtriClip System, which has been used to treat more than 750,000 patients worldwide. The company's pain management solutions include cryoSPHERE probes for Cryo Nerve Block therapy and the recently launched cryoXT probes designed for post-amputation pain management.

AtriCure maintains a direct sales force of approximately 330 employees in the United States and approximately 75 employees in international direct markets including Germany, France, the United Kingdom, the Benelux region, Canada, and Australia. The company also operates through a network of distributors in Asia, South America, and select European countries. The company holds multiple FDA clearances and approvals, including the only FDA-approved devices for treating long-standing persistent atrial fibrillation in both concomitant and standalone settings.

The company invests significantly in clinical science through landmark trials including BoxX-NoAF, LeAAPS, HEAL-IST, and CONVERGE studies to validate long-term results and support regulatory applications for expanded indications. AtriCure's competitive position is strengthened by its comprehensive product portfolio, established physician relationships, and published clinical evidence demonstrating superior outcomes compared to alternative treatment approaches. The company addresses substantial market opportunities, with estimates indicating that less than fifteen percent of eligible open-heart surgery patients currently receive surgical ablation treatment.